392 results
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.
(c) The term
8-K
dsw5p
1 Dec 23
Entry into a Material Definitive Agreement
8:25am
8-K/A
EX-99.1
nfyqzwzj bctulunx4
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
x91e6u
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
ln5dj125 um
18 Oct 23
Other Events
9:03am
8-K
EX-10.1
fdvb48y
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
3w9hscyvm2er
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
x2gqu3i72qx vpilqk
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
S-3ASR
EX-1.2
xa8npz3y4
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-4.3
aiwnro
30 Sep 22
Automatic shelf registration
4:17pm
425
EX-99.1
v159 hg5u
21 Jun 22
Business combination disclosure
8:00am